Advanced search
Start date
Betweenand

Center of Research and Development in Immunobiologicals

Grant number: 20/07040-1
Support type:Research Grants - Problem-Oriented Research Centers in São Paulo
Duration: June 01, 2021 - May 31, 2026
Field of knowledge:Health Sciences - Collective Health - Public Health
Principal researcher:Ana Maria Moro
Grantee:Ana Maria Moro
Home Institution: Instituto Butantan. Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
Pesquisadores principais:
Esper Georges Kallás ; Paulo Lee Ho ; Rui Curi
Assoc. researchers:Ana Marisa Chudzinski-Tavassi ; Ana Priscila Perini de Araújo ; Aryene Góes Trezena ; Carla Lilian de Agostini Utescher ; Carolina Luísa Alves Barbieri ; Cássia Gisele Terrassani Silveira ; Cristiano Gonçalves Pereira ; Débora Botéquio Moretti ; Denise Cristina André Oliveira ; Dimas Tadeu Covas ; Fabio Eudes Leal ; Flávia Ferreira Barbosa ; Juliana Zanatta de Carvalho Dias ; Lilian Rumi Tsuruta Sagawa ; Maria Do Carmo Sampaio Tavares Timenetsky ; Milena Apetito Akamatsu ; Milene Tino De Franco ; Patricia Antonia Estima Abreu de Aniz ; Raul Machado Neto ; Renato Mancini Astray ; Ricardo das Neves Oliveira ; Ricardo Palacios Gomez ; Sonia Aparecida de Andrade Chudzinski ; Soraia Attie Calil Jorge ; Tânia Maria Manieri ; Thiago Rennó dos Mares Guia ; Vanda Dolabela de Magalhães ; Vânia Gomes de Moura Mattaraia ; Viviane Fongaro Botosso ; Wagner Quintilio
Associated scholarship(s):22/00205-0 - Evaluation of neutralization activity of anti-tetanus monoclonal antibodies in cellular assays, BP.MS
22/00228-0 - Development of human monoclonal antibodies to influenza virus from Fab fragment library, BP.DR

Abstract

Instituto Butantan (IB), has always worked to answer public health challenges and has a long tradition in the development and manufacturing of vaccines and antibodies. This project addresses both areas, influenza vaccines and human monoclonal antibodies, focusing on critical targets that demand attention and require the use of strategies based on solid scientific, clinical, regulatory and organizational knowledge. For this demand, the multidisciplinary Center for R&D in Immunobiologics (CeRDI) is articulated between research institutions and companies with common objectives to achieve the intended goals. The communication between the partners, initiated with the Center's nucleation, revealed the enthusiasm in the construction of this proposal and the determination to seek solutions with state-of-the-art technologies. As the largest manufacturer of influenza vaccine in the southern hemisphere, Butantan has in recent years met the challenge of achieving national autonomy by increasing the productive capacity of the influenza vaccine to up to 75 million doses annually. With the creation of these core of competences, we have the opportunity to advance in innovative and non-trivial aspects to increase vaccination coverage, related to the quadrivalent vaccine, such as the adjuvant formulation and high-dose formulation. We aim also on the development of new influenza vaccines, such as a cell-culture based vaccine, and broadspectrum vaccine, the latter a globally sought for solution. On the other hand, this Center will dedicate to advancing the current development of neutralizing human monoclonal antibodies (humAbs), based on platforms established separately at Butantan and at the University of São Paulo Medical School (FMUSP), focusing on anti-tetanus toxin mAbs, anti-Zika virus (ZIKV) mAbs , antiyellow fever virus (wtYFV) mAbs and anti-influenza viruses mAbs (H7N9 and elicited by universal vaccine vaccinated people). Obtained from gene sequences of antibodies produced by memory B lymphocytes or plasmablasts, humAbs have the advantage of being selected in vivo. The platform, based on the identification of the antibody sequences through the generation of stable cell lines, will allow for the production of antibodies with therapeutic potential to control serious public health problems. CeRDI counts on partnerships between Butantan Institute/Butantan Foundation and the University of São Paulo, besides researches from the Instituto Adolfo Lutz and Oxford University. A partnership with the Universidade Municipal de São Caetano do Sul aims to create a territory of excellence in clinical effectiveness assessment tests, and to nucleate competences in the area. CeRDI counts on the participation of Bionovis SA (Brazil) and the startups Blue Waters Vaccines and Mabloc, based on USA. The conjunct action of institutions and companies, acting in complementary and competence, will allow for the improvement and development of biopharmaceutical products, a strategic and desirable condition for the immunobiologicals industry in our country. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
AKAMATSU, MILENA; DE CASTRO, TAVARES; TAKANO, CAROLINA YUMI; HO, PAULO LEE. Off balance: Interferons in COVID-19 lung infections. EBIOMEDICINE, v. 73, . (20/07040-1)

Please report errors in scientific publications list by writing to: cdi@fapesp.br.